#1 Clinical Trials Search in Europe

Anti-Il-8 Human Monoclonal Antibody

This article discusses the use of Anti-IL-8 Human Monoclonal Antibody (BMS-986253) in clinical trials for advanced cancers. The drug is being studied in combination with other immunotherapy treatments to evaluate its safety, efficacy, and potential benefits for patients with various types of advanced solid tumors and early-stage colon cancer. These trials aim to determine the optimal dosage, assess treatment responses, and identify potential biomarkers for predicting treatment outcomes.

Table of Contents

What is ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY?

ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY, also known as BMS-986253 or anti-IL8 mAb, is an experimental medication being studied for the treatment of advanced cancers[1]. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-created proteins designed to target specific molecules in the body.

How Does It Work?

This medication works by targeting and blocking interleukin-8 (IL-8), a protein in the body that can promote cancer growth and spread. By inhibiting IL-8, researchers hope to slow down or stop cancer progression[1]. The drug is being studied as part of a new approach called immunotherapy, which aims to boost the body’s own immune system to fight cancer.

What Conditions Does It Treat?

ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY is currently being investigated for the treatment of:

  • Advanced solid tumors: These are cancers that form solid masses in the body and have spread beyond their original location[1].
  • Non-small cell lung carcinoma (NSCLC): A type of lung cancer that is being studied in some parts of the clinical trials[1].
  • Early-stage colon cancer: The drug is being tested as a pre-surgery treatment for patients with colon cancer that has not yet spread to other parts of the body[2].

Current Clinical Trials

There are currently two main clinical trials studying this medication:

  1. A Phase 1/2 study combining ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY with other cancer drugs (nivolumab and ipilimumab) in patients with advanced cancers[1]. This study aims to:
    • Determine the safety and best dose of the medication
    • Evaluate how well the combination treatment works
    • Study how the body processes the drug
    • Measure changes in IL-8 levels in the blood during treatment
  2. A Phase 2 study (called the NICHE trial) testing the medication as a pre-surgery treatment for early-stage colon cancer[2]. This study aims to:
    • Assess the safety and feasibility of using immunotherapy before colon cancer surgery
    • Measure how well the treatment shrinks tumors
    • Identify biomarkers that could predict treatment response
    • Study how the treatment affects the immune system in the tumor

How Is It Administered?

ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY is given as an intravenous infusion, which means it’s delivered directly into the bloodstream through a vein[1][2]. The exact dosing and frequency of administration are still being determined through clinical trials.

Potential Side Effects

As this is an experimental medication, the full range of side effects is not yet known. However, potential side effects may include:

  • Immune-related adverse reactions, as the drug affects the immune system
  • Infusion-related reactions
  • Fatigue
  • Nausea
  • Decreased appetite
It’s important to note that side effects can vary depending on the individual and the combination of treatments used[1][2].

Future Research and Potential

Research on ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY is ongoing, and scientists are exploring its potential in various ways:

  • Combining it with other immunotherapy drugs to enhance effectiveness
  • Using it as a pre-surgery treatment to potentially improve surgical outcomes
  • Identifying biomarkers that could predict which patients are most likely to benefit from the treatment
  • Studying its effects on different types of cancer
As research progresses, we may learn more about the drug’s effectiveness, optimal dosing, and potential for treating various types of cancer[1][2].

Aspect Details
Drug Name Anti-IL-8 Human Monoclonal Antibody (BMS-986253)
Administration Intravenous infusion
Cancer Types Studied Advanced solid tumors, Non-small cell lung carcinoma, Early-stage colon cancer
Main Objectives Safety assessment, Optimal dosage determination, Efficacy evaluation, Biomarker identification
Combination Therapies Nivolumab, Ipilimumab, Relatlimab
Key Endpoints Safety, Feasibility, Pathological response rate, Disease-free survival
Eligibility Criteria Age ≥18, Specific tumor types, Accessible tumor for biopsy, Adequate organ function

FAQ

  • What is Anti-IL-8 Human Monoclonal Antibody? Anti-IL-8 Human Monoclonal Antibody, also known as BMS-986253, is an experimental medication being studied for its potential to treat advanced cancers. It is designed to target and block the IL-8 protein, which may play a role in cancer growth and progression.
  • What types of cancers are being studied with this drug? The drug is being investigated for various advanced solid tumors, including non-small cell lung carcinoma (NSCLC) and early-stage colon cancer. It is being studied both as a standalone treatment and in combination with other immunotherapy drugs.
  • How is the drug administered? Anti-IL-8 Human Monoclonal Antibody is administered as a solution for intravenous infusion. This means it is given directly into the bloodstream through a vein.
  • What are the main objectives of these clinical trials? The main objectives include determining the safety and optimal dosage of the drug, assessing its effectiveness in treating advanced cancers, studying how the body processes the drug, and evaluating potential biomarkers that may predict treatment response.
  • Are there any specific eligibility criteria for participating in these trials? Yes, there are specific eligibility criteria. Generally, participants must have advanced solid tumors, be at least 18 years old, and meet certain health criteria. Some trials may have additional requirements, such as having tumors accessible for biopsy or specific cancer types like colon cancer.

Ongoing Clinical Trials on Anti-Il-8 Human Monoclonal Antibody

  • Study on Pre-Surgery Immunotherapy with Relatlimab, Anti-IL-8 mAb, and Ipilimumab for Early-Stage Colon Cancer Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of BMS-986253 with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Spain

Glossary

  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In cancer treatment, monoclonal antibodies can be used to deliver drugs directly to cancer cells or to block certain proteins that help cancer grow.
  • IL-8: Interleukin-8, a protein in the body that can promote inflammation and potentially contribute to cancer growth and spread.
  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer. It works by stimulating your own immune system to work harder or by giving you man-made versions of immune system components.
  • Solid Tumor: An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer) or malignant (cancer).
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Neoadjuvant Therapy: Treatment given before the main treatment. In cancer, neoadjuvant therapy is often given to shrink a tumor before surgery.
  • Pathological Response: The effect of treatment on cancer cells as seen under a microscope. A complete pathological response means no cancer cells are found after treatment.
  • Disease-Free Survival (DFS): The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.

References

  1. http://clinicaltrials.eu/trial/study-of-bms-986253-with-nivolumab-and-ipilimumab-for-patients-with-advanced-solid-tumors/
  2. http://clinicaltrials.eu/trial/study-on-pre-surgery-immunotherapy-with-relatlimab-anti-il-8-mab-and-ipilimumab-for-early-stage-colon-cancer-patients/